ADCs

News

Pfizer’s new cancer unit sees eight new blockbusters by 2030

Fresh from the $43 billion acquisition of antibody-drug conjugate (ADC) specialist Seagen, Pfizer has laid out plans for its dedicated oncology division in front of invest

R&D

This week in clinical trials: 22nd to 26th January 2024

And so, our weekly clinical trials round-ups continue.

News

Update: Orion buys stake in LegoChem as biotech push goes on

Food group Orion Group has taken a 25% in South Korean biotech LegoChem Bioscience, becoming its largest shareholder, as part of a push into the biotech sector.

R&D

Big pharma places big bets on antibody-drug conjugates

Antibody-drug conjugates have emerged as one of the most popular treatment modalities for investment in recent years.

Oncology

ADCs shine at ESMO ’23, as pharma makes case for early immun...

Antibody-drug conjugates (ADCs) took centre stage at the European Society of Medical Oncology (ESMO) Congress in Madrid 20th-24th October, which was back at full capac

Partner Content